There have been more than 60 deals in the diagnostic space, and some anticipate an uptick in deals in 2024. Nevertheless, the bar is unquestionably higher than it's ever been for diagnostic companies, and a recent survey found that 29% of CEOs in the space said they were ill-prepared to attract sufficient funding to develop and launch a new product; that number increased for the smallest companies – with 47% saying they were ill-prepared. This panel includes advanced and emerging leaders of diagnostics companies, venture capitalists and organizers of coalitions geared toward funding diagnostic ideas. Together, they will examine the current funding landscape for diagnostic technologies, discuss how they’re focusing their businesses, and explore new funding strategies.